Chemoprevention of prostate cancer with the polyamine synthesis inhibitor difluoromethylornithine

Recent Results in Cancer Research

Volumn 202, Issue , 2014, Pages 115-120

  Meyskens, Frank L ^a,b   Simoneau, Anne R ^a,b   Gerner, Eugene W ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFLORNITHINE; PLACEBO; POLYAMINE; ORNITHINE DECARBOXYLASE; PROSTATE SPECIFIC ANTIGEN; PUTRESCINE; SPERMIDINE; SPERMINE;

ARTICLE; CANCER PREVENTION; CHEMOPROPHYLAXIS; DRUG EFFECT; DRUG RESPONSE; GLEASON SCORE; HUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE VOLUME; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; TREATMENT OUTCOME; AMINE SYNTHESIS; CANCER GROWTH; DRUG EFFICACY; HIGH RISK POPULATION; OUTCOME ASSESSMENT; PATIENT SELECTION; PROSTATE BIOPSY; STUDY DESIGN; SYNTHESIS; TREATMENT DURATION;

BIOSYNTHETIC PATHWAYS; CHEMOPREVENTION; CLINICAL TRIALS AS TOPIC; EFLORNITHINE; ENZYME INHIBITORS; HUMANS; MALE; ORNITHINE DECARBOXYLASE; POLYAMINES; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 84958537391     PISSN: 00800015     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-45195-9_14     Document Type: Article

References (22)

1. Agostinelli E, Marques MP, Calheiros R, Gil FP, Tempera G, Viceconte N, Battaglia V, Grancara S, Toninello A (2010) Polyamines: fundamental characters in chemistry and biology. Amino Acids 38(2): 393-403. doi:10.1007/s00726-009- 0396-7. Epub 2009 Dec 15. Review. PubMed PMID: 20013011
2. Algotar AM, Stratton MS, Ahmann FR, Ranger-Moore J, Nagle RB, Thompson PA, Slate E, Hsu CH, Dalkin BL, Sindhwani P, Holmes MA, Tuckey JA, Graham DL, Parnes HL, Clark LC, Stratton SP (2013) Phase 3 clinical trial investigating the effect of selenium supplementation in men at high-risk for prostate cancer. Prostate 73(3): 328-335. doi:10.1002/pros.22573. Epub 2012 Aug 10. PubMed PMID: 22887343
3. Cimino S, Sortino G, Favilla V, Castelli T, Madonia M, Sansalone S, Russo GI, Morgia G (2012) Polyphenols: key issues involved in chemoprevention of prostate cancer. Oxid Med Cell Longev 2012: 632959. doi:10.1155/2012/632959. Epub 2012 May 28. Review. PubMed PMID: 22690272; PubMed Central PMCID: PMC3368543
4. Earnshaw SR, Brogan AP, McDade CL (2013) Model-based cost-effectiveness analyses for prostate cancer chemoprevention: a review and summary of challenges. Pharmacoeconomics 31(4): 289-304. doi:10.1007/s40273-013-0037-6. PubMed PMID: 23519744
5. Gee J, Bailey H, Kim K, Kolesar J, Havighurst T, Tutsch KD, See W, Cohen MB, Street N, Levan L, Jarrard D, Wilding G (2013) Phase II open label, multi-center clinical trial of modulation of intermediate endpoint biomarkers by 1a-hydroxyvitamin D2 in patients with clinically localized prostate cancer and high grade pin. Prostate. Jan 17. doi:10.1002/pros.22644. [Epub ahead of print] PubMed PMID: 23335089
6. Gerner EW, Meyskens FL Jr. (2004) Polyamines and cancer: old molecules, newunderstanding. Nat Rev Cancer 4(10): 781-792. Review. PubMed PMID: 15510159
7. Horie S (2012) Chemoprevention of prostate cancer: soy isoflavones and curcumin. Korean J Urol 53(10): 665-672. doi:10.4111/kju.2012.53.10.665. Epub 2012 Oct 19. PubMed PMID: 23136625; PubMed Central PMCID: PMC3490085
8. Kadmon D (1992) Chemoprevention in prostate cancer: the role of difluoromethylornithine (DFMO). J Cell Biochem Suppl 16H: 122-127. Review.PubMed PMID: 1289667
9. Kreul SM, Havighurst T, Kim K, Mendonça EA, Wood GS, Snow S, Borich A, Verma A, Bailey HH (2012) A phase III skin cancer chemoprevention study of DFMO: long-term follow-up of skin cancer events and toxicity. Cancer Prev Res (Phila) 5(12): 1368-1374. doi:10.1158/1940-6207.CAPR-12-0233. Epub 2012 Oct 11. PubMed PMID: 23060038; PubMed Central PMCID: PMC3518692
10. McLaren CE, Fujikawa-Brooks S, Chen WP, Gillen DL, Pelot D, Gerner EW, Meyskens FL Jr (2008) Longitudinal assessment of air conduction audiograms in a phase III clinical trial of difluoromethylornithine and sulindac for prevention of sporadic colorectal adenomas. Cancer Prev Res (Phila) 1(7): 514-521. doi:10.1158/1940-6207.CAPR-08-0074. PubMed PMID: 19139001; PubMed Central PMCID: PMC2702261
11. Meyskens FL Jr, McLaren CE, Pelot D, Fujikawa-Brooks S, Carpenter PM, Hawk E, Kelloff G, Lawson MJ, Kidao J, McCracken J, Albers CG, Ahnen DJ, Turgeon DK, Goldschmid S, Lance P, Hagedorn CH, Gillen DL, Gerner EW (2008) Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, doubleblind trial. Cancer Prev Res (Phila) 1(1): 32-38. doi:10.1158/1940-6207.CAPR-08-0042. PubMed PMID: 18841250; PubMed Central PMCID: PMC2562024
12. Nowotarski SL, Woster PM, Casero RA Jr (2013) Polyamines and cancer: implications for chemotherapy and chemoprevention. Expert Rev Mol Med 15:e3. doi:10.1017/erm.2013.3. PubMed PMID: 23432971
13. Ozten-Kandas N, Bosland MC (2011) Chemoprevention of prostate cancer: Natural compounds, antiandrogens, and antioxidants - In vivo evidence. J Carcinog 10: 27. doi:10.4103/1477-3163. 90438. Epub 2011 Nov 30. PubMed PMID: 22190869; PubMed Central PMCID: PMC3243088
14. Pan DL, Samavedi S, Eldefrawy A, Manoharan M (2012) The current status of active surveillance for prostate cancer. Postgrad Med 124(3): 50-58. doi:10.3810/pgm.2012.05.2548. Review. PubMed PMID: 22691899
15. Samal K, Zhao P, Kendzicky A, Yco LP, McClung H, Gerner E, Burns M, Bachmann AS, Sholler G (2013) AMXT-1501, a novel polyamine transport inhibitor, synergizes with DFMO in inhibiting neuroblastoma cell proliferation by targeting both ornithine decarboxylase and polyamine transport. Int J Cancer. Mar 2. doi:10.1002/ijc.28139. [Epub ahead of print] PubMed PMID: 23457004
16. Seiler N (2003) Thirty years of polyamine-related approaches to cancer therapy. Retrospect and prospect. Part 1. Selective enzyme inhibitors. Curr Drug Targets 4(7): 537-564. Review. PubMed PMID: 14535654
17. Simoneau AR, Gerner EW, Phung M, McLaren CE, Meyskens FL Jr (2001) Alphadifluoromethylornithine and polyamine levels in the human prostate: results of a phase IIa trial. J Natl Cancer Inst 93(1): 57-59. PubMed PMID: 11136843
18. Simoneau AR, Gerner EW, Nagle R, Ziogas A, Fujikawa-Brooks S, Yerushalmi H, Ahlering TE, Lieberman R, McLaren CE, Anton-Culver H, Meyskens FL Jr (2008) The effect of difluoromethylornithine on decreasing prostate size and polyamines in men: results of a yearlong phase IIb randomized placebo-controlled chemoprevention trial. Cancer Epidemiol Biomarkers Prev 17(2): 292-299. doi:10.1158/1055-9965.EPI-07-0658. PubMed PMID: 18268112; PubMed Central PMCID: PMC2515594
19. Taneja SS, Morton R, Barnette G, Sieber P, Hancock ML, Steiner M (2013) Prostate cancer diagnosis among men with isolated high-grade intraepithelial neoplasia enrolled onto a 3-year prospective phase III clinical trial of oral toremifene. J Clin Oncol 31(5): 523-529. doi:10. 1200/JCO.2012.41.7634. Epub 2013 Jan 7. PubMed PMID: 23295793
20. Thapa D, Ghosh R (2012) Antioxidants for prostate cancer chemoprevention: challenges and opportunities. Biochem Pharmacol 83(10): 1319-1330. doi:10.1016/j.bcp.2011.12.027. Epub 2012 Jan 11. Review. PubMed PMID: 22248733
21. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA Jr (2003) The influence of finasteride on the development of prostate cancer. N Engl J Med 349(3): 215-224. Epub 2003 Jun 24. PubMed PMID: 12824459
22. Zell JA, McLaren CE, Chen WP, Thompson PA, Gerner EW, Meyskens FL (2010) Ornithine decarboxylase-1 polymorphism, chemoprevention with eflornithine and sulindac, and outcomes among colorectal adenoma patients. J Natl Cancer Inst 102(19): 1513-1516. doi:10.1093/jnci/djq325. Epub 2010 Aug 26. PubMed PMID: 20798393; PubMed Central PMCID: PMC2950167